Maze Therapeutics, Inc./$MAZE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Maze Therapeutics, Inc.

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Ticker

$MAZE
Sector
Primary listing

Employees

125

MAZE Metrics

BasicAdvanced
$666M
-
-$3.82
-
-

Bulls say / Bears say

Maze closed Q2 2025 with $264.5 million in cash and equivalents, which is enough to fund operations into the second half of 2027 and advance both clinical programs without immediate funding pressure.
The Phase 1 study for MZE782 in healthy volunteers is on schedule to produce proof-of-mechanism biomarker data in Q3 2025, representing a near-term catalyst that could validate the drug’s potential in CKD and PKU.
Maze’s expanded IPO in February 2025 raised $140 million in gross proceeds, reflecting strong investor confidence and securing the financial base needed to further develop its precision medicine pipeline.
Both lead programs do not yet have clinical proof-of-concept, with Phase 1 mechanistic data for MZE782 not expected until Q3 2025 and Phase 2 data for MZE829 anticipated in Q1 2026, exposing investors to high execution risk.
MZE829 is focused on APOL1-mediated kidney disease—a genetically defined segment mainly affecting those of West African descent—potentially limiting its market size and making trial enrollment challenging due to the need for genetic screening.
Maze has not generated product revenue and admits it might run out of cash sooner than expected, which could require new funding and potentially dilute existing shareholders if development timelines slip beyond the current cash runway.
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MAZE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs